Erbicin-derived immunoagents (EDIAs) were found to be selectively cytotoxic for ErbB2-positive cancer cells (including those resistant to Trastuzumab) in vitro and in vivo, to recognize an epitope different from that of Trastuzumab and Pertuzumab [18], and not to be cardiotoxic [19,20]. Here, ERBB2 is linked to cancer.